Horseshoes, hand grenades, and body-surface area-based dosing: Aiming for a target

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 182-183

  Egorin, Merrill J ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

AREA UNDER THE CURVE; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; EDITORIAL; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MEDICAL PRACTICE; NONHUMAN; PERIPHERAL NEUROPATHY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; METABOLISM; NEOPLASM; NOTE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY SURFACE AREA; CLINICAL TRIALS; HUMANS; NEOPLASMS; PACLITAXEL;

EID: 0037440047     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.084     Document Type: Editorial

References (7)

1. Dedrick RL: Animal scale-up. J Pharmacokinet Biopharm 1:435-462, 1973
2. Freireich EJ, Gehan EA, Rall DP, et al: Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey, and man. Cancer Chemother Rep 50:219-244, 1966
3. Grochow LB, Baraldi C, Noe D: Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82:323-325, 1990
4. Reilly JJ, Workman P: Normalization of anti-cancer drug dosage using body weight and surface area: Is it worthwhile? Cancer Chemother Pharmacol 32:411-418, 1993
5. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
6. Sawyer M, Ratain MJ: Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177, 2001
7. Smorenburg C, Sparreboom A, Bontenbal M et al: Randomized-Crossover Evaluation of Body-Surface Area-Based Dosing Versus Flat-Fixed Dosing of Paclitaxel. J Clin Oncol 21:197-202, 2003